Onxeo has engaged MCT (Regional CRO specialized on Middle East and Africa) to expand “Relieve” phase III HCC study in 3 Middle East countries (Lebanon, Egypt and Saudi Arabia). More information in Onxeo press release: 150326EN_Livatag
MCT’s collaboration with Onxeo on HCC Phase III study in Middle East
Related Posts
-
MCT open an office in Dakar to better ...
Read more... -
MCT will organize a Webinar on ...
Read more... -
MCT attended the 2019 Clinical ...
Read more... -
MCT leads Workshop on "Clinical ...
Read more... -
MCT is looking for Senior Clinical ...
Read more... -
MCT team meets Tunisian health ...
Read more... -
MCT is pleased to communicate about ...
Read more... -
MCT attended PCMG 2020 live on June ...
Read more... -
MCT inaugurates in April 15 it new ...
Read more... -
MCT Quality Manager Alexa Younes has ...
Read more... -
MCT expand to West and Sub Saharan ...
Read more... -
Following inspection, MCT local team ...
Read more... -
Onxeo has engaged MCT (Regional CRO ...
Read more... -
MCT Clinical Project Lead Marwan ...
Read more...